ERLEADA® demonstrated a high tumor-to-plasma ratio in a preclinical mouse xenograft model of prostate cancer2
Mechanism of Action (MOA)
ERLEADA® is an androgen receptor (AR) inhibitor indicated to treat mCSPC and nmCRPC1
ERLEADA® inhibits AR signaling at multiple sites of action1:
- Binds directly to the ligand-binding domain of the AR
- Inhibits AR nuclear translocation
- Inhibits DNA binding
- Impedes AR-mediated transcription
In preclinical and phase 1 studies*:
*Clinical significance is unknown.
ERLEADA® retained antagonistic activity in the setting of AR overexpression in a preclinical binding affinity assay using human prostate cancer cells2
Dose escalation of ERLEADA® to 480 mg/day (twice the approved daily dose) did not identify a maximum-tolerated dose in a phase 1 study of 30 patients with progressive, metastatic CRPC3
CRPC = castration-resistant prostate cancer; mCSPC = metastatic castration-sensitive prostate cancer; nmCRPC = non-metastatic castration-resistant prostate cancer.
1. ERLEADA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
2. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1494-1503.
3. Rathkopf DE, Morris MJ, Fox JJ, et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2013;31(28):3525-3530.